bioRxiv Science⌕ Search

Biology subjects

Seijas-Gamardo, A.

Publications and source records attributed to Seijas-Gamardo, A..

2 recordsLinked to original sources

Packed for Ossification: High-Density Bioprinting of hPDC Spheroids in HAMA for Endochondral Ossification

Long bone fractures are primarily repaired through endochondral ossification, a process in which a soft cartilage template forms at the injury site and is gradually replaced by bone. While bone has an innate self-healing capacity, this process can be disrupted in cases of large or complex defects, where regeneration fails, and clinical intervention is required. This study aimed at the development of a tissue engineering approach using human periosteum-derived cell (hPDC) spheroids encapsulated or bioprinted at high density within hyaluronic acid methacrylate (HAMA) hydrogels to support hypertrophic cartilage formation as a template for endochondral bone regeneration. We first compared different encapsulation time points (days 1, 7, and 14), finding that early encapsulation (day 1) enhanced spheroid fusion, increased DNA content, and promoted hypertrophic cartilage formation, as indicated by greater glycosaminoglycan (GAG) and collagen deposition along with lacunae formation. Next, HAMA-encapsulated spheroids were compared to spheroids formed using a standardized microwell platform, demonstrating that encapsulation promoted a more mature cartilage-like matrix with thicker collagen fibers and enhanced hypertrophic differentiation. Gene expression and immunostaining confirmed progression toward hypertrophic and osteogenic phenotypes. Finally, extrusion-based bioprinting of HAMA bioinks comprising a high-density of hPDC spheroids demonstrated scalability, improved spheroid alignment, and maintained robust cell viability and hypertrophic differentiation. HAs bioactivity and regulatory advantages support clinical translation, although achieving spatial control remains an area for further optimization. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/674866v2_ufig1.gif" ALT="Figure 1"> View larger version (67K): org.highwire.dtl.DTLVardef@40b55eorg.highwire.dtl.DTLVardef@434b2corg.highwire.dtl.DTLVardef@1fc4640org.highwire.dtl.DTLVardef@168252e_HPS_FORMAT_FIGEXP M_FIG C_FIG

cell biology↗

Dimethyl sulfoxide primes induced pluripotent stem cells for more efficient nephron progenitor and kidney organoid differentiation

The field of human induced pluripotent stem cells (hiPSCs) has seen significant progress since the discovery of reprogramming somatic cells using the transcription factors Oct4, Sox2, Klf4, and c-Myc. hiPSCs are similar to embryonic stem cells in a primed state of pluripotency and has the potential to differentiate into any adult human cell type, offering a versatile tool for research and potential therapeutic applications. However, the efficiency of differentiation protocols for generating complex structures with multiple cell types, like kidney organoids, remains a challenge. This study investigates the impact of treating hiPSCs with a low-dose dimethyl sulfoxide to enhance kidney organoid differentiation using a well-established protocol from literature. We found that treating hiPSCs with 1-2% DMSO affects gene expression of pluripotent transcription factors, hiPSC colony morphology, and enhances the expression of key metanephric mesenchyme nephron progenitor marker, SIX2 after 9 days of kidney organoid differentiation. Our findings also suggest that DMSO treatment helps improve hiPSC differentiation protocol efficiency toward the development of tubular kidney organoids. Further research is needed to elucidate the mechanisms underlying these effects and to refine the differentiation process for potential in vitro research applications in biomedical research and drug development.

cell biology↗